Bioprosthetic Valve Thrombosis while on a Novel Oral Anticoagulant for Atrial Fibrillation.

ABSTRACT: Highlights•BPVT occurred while on a DOAC for treatment of AF.•Echocardiographic and pathologic images of BPVT are shown.•The definition of NVAF is not uniform in clinical trials or guidelines.•The optimal anticoagulation strategy for BPV and AF is unclear.•Caution is advised in using DOACs for AF in patients with BPVs.

SUBMITTER: O'Callaghan M 

PROVIDER: S-EPMC6058412 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other